Anti-citrullinated protein antibodies have a low avidity compared to antibodies against recall-antigens

Suwannalai, Parawee; Scherer, Hans Ulrich; Woude, Diane van der; Ioan-Facsinay, A.; Zijde, C.M. Jol van der; Tol, Maarten J. van; Huizinga, T.; Toes, R.E.M.; Trouw, Leendert A.

doi:10.1136/ard.2010.129577p

Cited by 20 publications

(36 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there was no difference between AD patients and HI in the avidity of antibodies against the well-known recall antigen DT. These findings are consistent with the report that the avidity of anti-DT is significantly higher than the avidity of autoantibodies to anti-citrullinated protein antibodies (ACPAs), which are a well-known serological marker of rheumatoid arthritis (RA) [19]. We also tried the 8 M urea treatment of antigen-coated plates before the incubation of 8 different IgG-anti-DFS70-positive sera and found little decrease in the titers (data not shown).…”

Section: Discussionsupporting

confidence: 80%

High-avidity IgG Autoantibodies against DFS70/LEDGF in Atopic Dermatitis

Watanabe¹,

Muro

Sugiura³

et al. 2013

J Clin Cell Immunol

View full text Add to dashboard Cite

Objective: Dense fine speckles 70 kDa protein (DFS70)/lens epithelium-derived growth factor (LEDGF) autoantibodies have been reported to be present in serum samples from patients with atopic dermatitis (AD) as well as from healthy individuals (HI). We previously revealed that IgE-and IgG4-anti-DFS70 autoantibodies were found in patients with AD and that their presence was associated with high levels of thymus-and activation-regulated chemokine. Our aim was to determine the avidity of IgG-anti-DFS70 antibodies in patients with AD relative to that avidity in HI. Patients and methods:This study was undertaken to measure the avidity of IgG-anti-DFS70 autoantibodies in AD and HI groups, in comparison with the major recall antigen diphtheria toxoid (DT) and to evaluate the relevance of IgG-anti-DFS70 autoantibodies to the disease. We measured the avidity of IgG-anti-DFS70 autoantibodies and anti-DT antibodies in sera that were positive for IgG-anti-DFS70 autoantibodies, obtained from 20 AD patients and 20 HI using enzyme-linked immunosorbent assay. Results:The avidity of anti-DFS70 autoantibodies was significantly higher (p<0.01) in the AD patients than in the HI, whereas there was no difference in the avidity of anti-DT between the two groups. There was also no positive correlation between the avidity and the titer of anti-DFS70 in the both groups. In contrast, positive correlation was shown between the serum levels and the avidities of anti-DT. Conclusion:Our findings indicate that AD patients might have significantly high-avidity IgG-anti-DFS70 autoantibodies and that this avidity might be a novel serological marker for a certain AD subpopulation.

show abstract

Section: Discussionsupporting

confidence: 80%

High-avidity IgG Autoantibodies against DFS70/LEDGF in Atopic Dermatitis

Watanabe¹,

Muro

Sugiura³

et al. 2013

J Clin Cell Immunol

View full text Add to dashboard Cite

show abstract

“…Bound human IgG or IgA was detected using rabbit anti-human IgG or IgA antibodies (Dako), followed by HRP-labeled goat anti-rabbit IgG antibody (Dako). Following the last washings, HRP enzyme activity was visualized using ABTS (34). A more detailed description of the protein modifications and ELISAs based on FCS and Fib, including F(ab′)2, is in SI Materials and Methods.…”

Section: Methodsmentioning

confidence: 99%

Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage

Shi

Knevel

Suwannalai

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

484

577

View full text Add to dashboard Cite

Autoimmune responses against posttranslationally modified antigens are a hallmark of several autoimmune diseases. For example, antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the prognosis and diagnosis of rheumatoid arthritis (RA), and have been implicated in disease pathogenesis. It is conceivable that other autoantibody systems, recognizing other posttranslationally modified proteins, are also present in RA. Here, we describe the presence of an autoantibody system that discriminates between citrulline- and homocitrulline-containing antigens in the sera of RA-patients. IgG antibodies recognizing carbamylated (homocitrulline-containing) antigens were present in sera of over 45% of RA-patients. Likewise, anticarbamylated protein (anti-CarP) IgA antibodies were observed in 43% of RA-sera. ACPA and anti-CarP antibodies are distinct autoantibodies because, in selected double-positive patients, the anti-CarP antibody binding to carbamylated antigens could be inhibited by carbamylated antigens, but not by control or citrullinated antigens. Similarly, ACPA-binding to citrullinated antigens could only be inhibited by citrullinated antigens. In line with this observation, 16% of ACPA-negative RA-patients, as measured by a standard ACPA assay, harbored IgG anti-CarP antibodies, whereas 30% of these patients tested positive for IgA anti-CarP antibodies. The presence of anti-CarP antibodies was predictive for a more severe disease course in ACPA-negative patients as measured by radiological progression. Taken together, these data show the presence of a unique autoantibody system recognizing carbamylated, but not citrullinated, protein antigens. These antibodies are predictive for a more severe clinical course in ACPA-negative RA-patients, indicating that anti-CarP antibodies are a unique and relevant serological marker for ACPA-negative RA.

show abstract

“…First, the avidity profile for each autoantibody (i.e., the percentage of autoantibody bound after elution with increasing concentrations of NaSCN) was determined based on the method described by Suwannalai et al (Suwannalai et al 2011); representative examples of the avidity profiles for three patients in samples taken at different time points are shown in Fig. 2 A-C.…”

Section: Avidity Of Fh Autoantibodiesmentioning

confidence: 99%

“…Avidity of the anti-FH autoantibodies was determined by ELISA, based on the method described by Suwannalai et al (Suwannalai et al 2011). An appropriate serum dilution for each sample was determined previously to ensure that binding to FH was not in saturation and that the OD value fell in the range of the standard curve.…”

Section: Avidity Determinationmentioning

confidence: 99%

Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome

Nozal

Bernabeu-Herrero

Uzonyi

et al. 2016

Molecular Immunology

View full text Add to dashboard Cite

Factor H (FH) autoantibodies are present in 6-10% of atypical hemolytic uremic syndrome (aHUS) patients, most of whom have homozygous deficiency of the FH-related protein FHR-1.Although the pathogenic role of the autoantibodies is established, little is known about their molecular characteristics and changes over time. Here, we describe the specificity and other immunological features of anti-FH autoantibodies in the Spanish and Hungarian aHUS cohorts.A total of 19 patients were included and serial samples of 14 of them were available. FH autoantibodies from FHR-1 deficient patients (n=13) mainly recognized FH, its SCR19-20 fragment and FHR-1, but autoantibody specificity in patients who are homo-or heterozygous for the CFHR1 gene (n=6)

show abstract

Anti-citrullinated protein antibodies have a low avidity compared to antibodies against recall-antigens

Cited by 20 publications

References 0 publications

High-avidity IgG Autoantibodies against DFS70/LEDGF in Atopic Dermatitis

High-avidity IgG Autoantibodies against DFS70/LEDGF in Atopic Dermatitis

Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage

Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome

Contact Info

Product

Resources

About